In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CellPro granted partial stay:

This article was originally published in Clinica

Executive Summary

CellPro has been granted a partial stay of the injunction covering its Ceprate SC stem cell concentration system, which has been found to infringe patents held by Johns Hopkins University. The product is licensed to Baxter and Becton Dickinson. A US court of appeals ruling has suspended provisions requiring CellPro to phase down non-US sales of disposable products for use with Ceprate by 25% a quarter in the 12 months to July 1998, pending review of the case on appeal. Total product sales were up by 27% to $8.1 million in the nine months. Net loss for the nine months was $16.6 million, down from $16.8 million.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts